cimicoxib
Small moleculeexperimental
Cimicoxib is a nonsteroidal anti-inflammatory drug (NSAID) used in veterinary medicine to treat dogs for pain and inflammation associated with osteoarthritis and for the management of pain and inflammation associated with surgery. It acts as a COX-2 inhibitor. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2007 (NCT00510822)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cyclooxygenase-2INHIBITOR
PTGS2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(-c2c(Cl)ncn2-c2ccc(S(N)(=O)=O)cc2)cc1F- Mol. weight
- 381.82 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCimicoxib ↗
- ChEMBLCHEMBL435381 ↗
Also known as
- cimicoxib
- cimicoxib
- cimicoxib
- cimicoxib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00510822 | Phase 2 | Oct 1, 2007 | Affectis Pharmaceuticals AG, FGK Clinical Research GmbH |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Affectis Pharmaceuticals AG | For profit | 1 | 1 | 1 | 2007 |
| FGK Clinical Research GmbH | For profit | 1 | 0 | 1 | 2007 |
2 organizations
Page 1 / 1